부산대학교 도서관

To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1468-2982.2006.00991.x Byline: MJA Lainez (1), S Evers (2), E Kinge (3), G Allais (4), C Allen (5), NA Rao (5), R Massaad (5), K Lis (5) Keywords: 5-HT/-receptor agonist; eletriptan; migraine; patient preference; rizatriptan wafer Abstract: Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. In this multicentre, open-label, two-period, crossover study, out-patients were randomly assigned to treat the first of two moderate to severe migraines with rizatriptan or eletriptan and the second with the alternate therapy. Patients completed diary assessments at baseline and up to 24 h after taking study medication. At the last visit, patients completed a psychometrically validated preference questionnaire. A total of 372 patients (mean age 38 years, 85% female) treated two migraine attacks, and 342 patients (92%) expressed a preference for treatment. Significantly more (P [less than or equal to] 0.001) patients preferred rizatriptan 10-mg wafer [61.1%; 95% confidence interval (CI) 55.7, 66.3] to eletriptan 40-mg tablet (38.9%; 95% CI 33.7, 44.3). The most common reason given for preference of either treatment was speed of headache relief. At 2 h, 80% and 69% of patients reported that rizatriptan and eletriptan, respectively, was convenient or very convenient to take (mean convenience score 1.99 vs. 2.31, respectively; P [less than or equal to] 0.001). Both triptans were well tolerated. In this head-to-head study designed to evaluate global patient preference, significantly more patients preferred the rizatriptan 10-mg wafer to the eletriptan 40-mg tablet for acute treatment of migraine. The single most important reason for preference was speed of relief, consistent with results from previous preference studies. Author Affiliation: (1)Hospital Clinico Universitario, University of Valencia, Valencia, Spain, (2)Department of Neurology, University of Munster, Munster, Germany, (3)Sandvika Neurologic Service, Sandvika, Norway, (4)Woman's Headache Centre, Department of Gynaecology and Obstetrics, University of Turin, Turin, Italy, and (5)Merck & Co, Inc., Whitehouse, NJ, USA Article History: Received 16 September 2004, accepted 18 March 2005 Article note: Miguel JA Lainez MD, PhD, Department of Neurology, Hospital Clinico Universitario, Universidad de Valencia, Avda. Blasco Ibanez, 17 46010 Valencia. Spain. Tel. + 34 9 6386 8863, fax + 34 9 6390 0321, e-mail jlaineza@meditex.es